Boston Scientific Corporation believes its electrophysiology (EP) pipeline will be “transformative” for the business and help the company make up ground on established players in the cardiac arrythmia ablation space.
According to a recent report from Meddevicetracker, Boston Scientific is the fourth biggest player in electrophysiology with just 7.7% of the worldwide cardiac catheter ablation market, but CEO Michael...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?